Group 1 (n=23) 58.7, 11.0 7/16 (30.4/69.5%) 12/11 (52.2/47.8%) 8/15 (34.8/65.2%) Group 2 (n=49) 62.6, 9.3 9/40 (18.4/81.6%) 24/25 (49.0/51.0%) 14/35 (28.6/71.4%) Group 3 (n=22) 63.0, 9.9 4/18 (18.2/81.8) 15/7 (68.2/31.3%) 8/14 (36.4/63.6%) Table 2. Pain, Disability and Participation Group 1 (n=23) Group 2 (n=49) Group 3 (n=22) mean (95% CI) mean (95% CI) mean (95% CI) those with early OA, 21% (5/23) intermittently used prescription medication, 65% used over the counter medication and 22% used glucosamine. Conclusions: People with early OA experience pain and disability although the trend is to a lesser degree than for those with moderate and end-stage OA, as expected. A proportion of individuals are seeking care. However, although the sample is small, these data highlight the need for a better understanding of this subgroup of people with early OA related to possible disease progression and interventions to ameliorate symptoms and disability. Background: Results of clinical trials in OA are usually reported as group comparisons of the mean (± standard deviation, sd) in score of the selected outcome. It might be more clinically relevant to show the results at a patient level, using a response criterion. Several response criteria are available: OARSI/OMERACT modified set of responder criteria [1], the Patient Acceptable Symptom State (PASS) [2] and the Minimum Clinically Important Improvement (MCII) [3]. Objectives: To assess differences in responder rates using various response criteria in a RCT in knee OA. Methods: Data were extracted from a prospective, multicentre, double-blind RCT comparing two hyaluronans over 24 weeks (F60027-Structovial and Hylan G-F 20-Synvisc) according to a
non inferiority design. The main outcome was the Lequesne index score (LFI). The secondary outcome was global pain on a Visual Analog Scale (VAS). 236 patients were available in the main analysis (per protocol analysis, PP). Demographic and knee OA characteristics were identical to those usually reported in knee OA trials. Since no value of the PASS is validated for the LFI yet, the results on pain VAS were used to classify patients as responders or not using OMERACT/OARSI modified criteria, PASS and MCII (using absolute value or % of improvement). Results are reported as mean (sd) and number (%).
Results: Table 1 below shows the response rates according to the different criteria. Rates of responders varied considerably: from 60 to 80% in each group and from 63% to 78% in the overall population (both treatment groups can be merged since non-inferiority was proven). The most liberal definition seems to be MCII (absolute), while the strictest appears to be PASS. Conclusions: Reporting clinical trial results at a patient level using response rates might be meaningful in knee OA. However this study clearly demonstrate that results significantly vary according to the response criterion used which is likely to lead to "positive" or "negative" results accordingly. More work is needed to help assessing the most clinically relevant response definition in knee OA.
